In November 1991, Merck Pharmaceutical Co. announced a landmark agreement to obtain samples of wild plants and animals for drug-screening purposes from Costa Rica's National Biodiversity Institute (INBIO). Spurred by this and other biodiversity prospecting ventures, interest in the commercial value of genetic and biochemical resources is burgeoning. This report is the first to provide systematic guidelines for establishing effective and equitable schemes for biodiversity prospecting.